Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders

References

• Lamy T, Moignet A, Loughran TP. Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129(9):1082–1094.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Cheon H, Dziewulska KH, Moosic KB, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep. 2020;15(2):103–112.
   PubMed Web of Science ®Google Scholar
• Viny AD, Maciejewski JP. High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. Leuk Lymphoma. 2015;56(2):503–504.
   PubMed Web of Science ®Google Scholar
• Dong N, Castillo Tokumori F, Isenalumhe L, et al. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021;96(7):772–780.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shah MV, Loughran TP. Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol. 2010;28(3):105–117.
   PubMed Web of Science ®Google Scholar
• He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127(24):3004–3014.
   PubMed Web of Science ®Google Scholar
• Barila G, Calabretto G, Teramo A, et al. T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best Pract Res Clin Haematol. 2019;32(3):207–216.
   PubMed Web of Science ®Google Scholar
• Semenzato G, Teramo A, Calabretto G, et al. All that glitters is not LGL leukemia. Leukemia. 2022;36(11):2551–2557.
   PubMed Web of Science ®Google Scholar
• Sun H, Wei S, Yang L. Dysfunction of immune system in the development of large granular lymphocyte leukemia. Hematology. 2019;24(1):139–147.
   PubMed Web of Science ®Google Scholar
• Isobe Y, Aritaka N, Setoguchi Y, et al. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol. 2012;65(3):278–282.
   PubMed Web of Science ®Google Scholar
• Ishida F. Aggressive NK-cell leukemia. Front Pediatr. 2018;6(292.
   PubMedGoogle Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18(4):763–770.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516.
   PubMed Web of Science ®Google Scholar
• Barila G, Teramo A, Calabretto G, et al. Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer J. 2018;8(6):51.
   PubMedGoogle Scholar
• Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–3057.
   PubMed Web of Science ®Google Scholar
• Zambello R, Teramo A, Gattazzo C, et al. Are T-LGL leukemia and NK-chronic lymphoproliferative disorder really two distinct diseases? Transl Med UniSa. 2014;8:4–11.
   PubMedGoogle Scholar
• Zambello R, Falco M, Della Chiesa M, et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood. 2003;102(5):1797–1805.
   PubMed Web of Science ®Google Scholar
• Zambello R, Teramo A, Barila G, et al. Activating KIRs in chronic lymphoproliferative disorder of NK cells: protection from viruses and disease induction? Front Immunol. 2014;5(72.
   PubMedGoogle Scholar
• Kawakami T, Sekiguchi N, Kobayashi J, et al. STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells. Int J Hematol. 2019;109(5):563–571.
   PubMed Web of Science ®Google Scholar
• Olson TL, Cheon H, Xing JC, et al. Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood. 2021;138(8):662–673.
   PubMed Web of Science ®Google Scholar
• Pastoret C, Desmots F, Drillet G, et al. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. Blood. 2021;137(23):3237–3250.
   PubMed Web of Science ®Google Scholar
• Kurt H, Jorgensen JL, Amin HM, et al. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018;100(5):444–454.
   PubMed Web of Science ®Google Scholar
• Gasparini VR, Binatti A, Coppe A, et al. A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer J. 2020;10(4):42.
   PubMed Web of Science ®Google Scholar